Did the study find differences in treatment responses between male and female VEXAS patients?
VEXAS syndrome is a rare autoinflammatory disorder caused by mutations in the UBA1 gene. Because this mutation occurs on the X chromosome, it primarily affects males. All major clinical studies reviewed found that their patient groups consisted exclusively of men. Consequently, these studies did not include female patients and could not measure or report differences in how men and women respond to treatments.
What the research says
A large retrospective study of 40 patients analyzed clinical features and treatment responses, but the entire group was male 1. This study noted that corticosteroids provided rapid early improvement while hypomethylating agents showed sustained responses over time, but it did not compare these results against a female cohort because none existed in the data 1.
Another study involving 42 patients from a Spanish cohort also confirmed that all enrolled individuals were male 4. The researchers found that glucocorticoids helped inflammatory symptoms but often led to dependence, and targeted therapies like decitabine improved hematologic issues. Since no women were in this group, no gender-based comparison of these outcomes was possible 4.
A third study from a Chinese hospital identified 16 male patients with the syndrome 3. These patients showed typical symptoms like anemia and skin lesions, and most received corticosteroids or immunosuppressants for relief. Like the other studies, this group contained only men, preventing any analysis of how female patients might differ in their treatment response 3.
An international multicenter study compared two specific drugs, anakinra and canakinumab, to see which worked better 6. This trial included 47 male patients and found that canakinumab led to better global responses and longer drug survival than anakinra 6. However, because the study population was strictly male, the results cannot be applied to women or used to determine if gender affects drug efficacy in VEXAS syndrome 6.
What to ask your doctor
- Are there any ongoing clinical trials that include female patients with VEXAS syndrome?
- How might my specific UBA1 mutation type influence my treatment options?
- What are the long-term risks of becoming dependent on corticosteroids for my condition?
- Could a combination of different drug classes help reduce my need for high-dose steroids?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.